Trial · NCT02898207
Results by group142
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 142
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Maximum Tolerated Dose (MTD) of Olaparib Administered in Combination With Onalespib | All Evaluable Participants | Dose Level 2 Olaparib PO BID | 300 | mg | |
| Maximum Tolerated Dose (MTD) of Olaparib Administered in Combination With Onalespib | All Evaluable Participants | Dose Level 2a Olaparib PO BID | 200 | mg | |
| Maximum Tolerated Dose (MTD) of Onalespib Administered in Combination With Olaparib | All Evaluable Participants | Dose Level 2 Onalespib IV on Days 1, 2, 8, 9, 15, and 16 | 40 | mg/m2 | |
| Maximum Tolerated Dose (MTD) of Onalespib Administered in Combination With Olaparib | All Evaluable Participants | Dose Level 2a Onalespib IV on Days 1, 2, 8, 9, 15, and 16 | 80 | mg/m2 | |
| Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) | Dose Level 0: Olaparib 200 mg and Onalespib 20 mg/m^2 | 0 | Participants | ||
| Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) | Dose Level 1: Olaparib 200 mg and Onalespib 40 mg/m^2 | 0 | Participants | ||
| Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) | Dose Level 2: Olaparib 300 mg and Onalespib 40 mg/m^2 | 0 | Participants | ||
| Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) | Dose Level 3: Olaparib 300 mg and Onalespib 80 mg/m^ | 0 | Participants | ||
| Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) | Dose Level 2a: Olaparib 200 mg and Onalespib 80 mg/m^2 | 2 | Participants | ||
| Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) | Dose Level 3a: Olaparib 200 mg and Onalespib 120 mg/m^2 | 1 | Participants | ||
| Number of Participants Who Experienced Treatment-Related Toxicities | Dose Level 0: Olaparib 200 mg and Onalespib 20 mg/m^2 | Diarrhea : Maximum Grade 1-2 | 3 | Participants | |
| Number of Participants Who Experienced Treatment-Related Toxicities | Dose Level 1: Olaparib 200 mg and Onalespib 40 mg/m^2 | Diarrhea : Maximum Grade 1-2 | 3 | Participants | |
| Number of Participants Who Experienced Treatment-Related Toxicities | Dose Level 2: Olaparib 300 mg and Onalespib 40 mg/m^2 | Diarrhea : Maximum Grade 1-2 | 3 | Participants | |
| Number of Participants Who Experienced Treatment-Related Toxicities | Dose Level 3: Olaparib 300 mg and Onalespib 80 mg/m^2 | Diarrhea : Maximum Grade 1-2 | 5 | Participants | |
| Number of Participants Who Experienced Treatment-Related Toxicities | Dose Level 2a: Olaparib 200 mg and Onalespib 80 mg/m^2 | Diarrhea : Maximum Grade 1-2 | 3 | Participants | |
| Number of Participants Who Experienced Treatment-Related Toxicities | Dose Level 3a: Olaparib 200 mg and Onalespib 120 mg/m^2 | Diarrhea : Maximum Grade 1-2 | 4 | Participants | |
| Number of Participants Who Experienced Treatment-Related Toxicities | Dose Level 0: Olaparib 200 mg and Onalespib 20 mg/m^2 | Diarrhea : Maximum Grade 3 | 0 | Participants | |
| Number of Participants Who Experienced Treatment-Related Toxicities | Dose Level 1: Olaparib 200 mg and Onalespib 40 mg/m^2 | Diarrhea : Maximum Grade 3 | 0 | Participants | |
| Number of Participants Who Experienced Treatment-Related Toxicities | Dose Level 2: Olaparib 300 mg and Onalespib 40 mg/m^2 | Diarrhea : Maximum Grade 3 | 0 | Participants | |
| Number of Participants Who Experienced Treatment-Related Toxicities | Dose Level 3: Olaparib 300 mg and Onalespib 80 mg/m^2 | Diarrhea : Maximum Grade 3 | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02898207/results